Last checked at 22 Dec 2016 09:47
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Result of General Meeting
Sareum (AIM: SAR), the specialist cancer drug discovery and development business, announces that at the General Meeting held earlier today, the resolution was duly passed.
For further information:
Sareum Holdings plc |
|
Tim Mitchell | 01223 497 700 |
WH Ireland Limited (Nominated Adviser and Co-Broker) | |
Chris Fielding / Nick Prowting | 020 7220 1666 |
Hybridan LLP (Co-Broker) |
|
Claire Noyce / William Lynne | 020 3764 2341/2342 |
The Communications Portfolio (Media enquiries) |
|
Ariane ComstiveAriane.comstive@communications-portfolio.co.uk | 07785 922 354 |
Notes for editors:
Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum operates an outsourced research model, working with international collaborators and a world-wide network of research providers. Its most advanced programme (Chk1) commenced clinical trials in May 2016 and was licensed to NASDAQ-listed ProNAi Therapeutics in September 2016.
SKIL(R) (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3 and TYK2 kinase cancer and autoimmune disease research programmes, which are in the IND-enabling preclinical and lead optimisation stages respectively. SKIL(R) can also generate drug research programmes against other kinase targets.
Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk